Domainex appoints Dr Bodo Spori as Head of Business Development for Europe

CAMBRIDGE, UK - Mar 12, 2018 - Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe. His appointment reflects Domainexs commitment to offering cutting-edge, integrated drug discovery services to an increasing number of customers across Europe, and supporting the discovery of innovative new therapeutic candidates to treat unmet human diseases.

Bodo Spori is a German neuroscientist, born and raised in Belgium, with more than 13 years of experience in strategic business development roles. He joins Domainex from Cyprotex, a subsidiary of Evotec AG, where he oversaw European and global sales initiatives in his role as VP of Business Development. Previously, he worked as the Senior European Business Development lead at Scottish Biomedical Ltd.

Domainex has an excellent reputation for delivering high quality drug discovery services to a global client base, said Dr Spori. Meeting Domainexs management team and scientists clearly illustrated their expertise and collaborative approach, which underpins the 'every compound counts' philosophy driving their growth. I also sensed the strong commitment to innovation that has led to both the development of Domainexs proprietary platforms, such as Combinatorial Domain Hunting, as well as several candidate drugs. I am delighted to be joining at such a dynamic and exciting time in the companys development, and look forward to bringing my own experience to help further advance the business.

I am delighted to welcome Bodo to Domainex, commented Dr Tom Mander, COO of the company. His successful track record of identifying and forging strategic client collaborations, coupled with his experience of working in the fields of assay development, protein production, in vitro and in vivo pharmacology, compound profiling, screening and ADME, make him the ideal addition to our business development team. Bodo will play a strategic role, building on our relationships with pharmaceutical and biotechnology companies across Europe and, via our services and expertise, help them advance their programmes towards development.

Ends

For more information contact:

Domainex
Dr Tom Mander
T: +44 (0)7584 578024
E: tom.mander@domainex.co.uk

Media Relations - Sciad Communications
Deborah Cockerill / Emma Pickup / Juliette Craggs
T: +44(0)20 7470 8801
E: domainex@sciad.com

Notes to Editors

About Domainex
Established in 2001 as a spin-out from University College London, Birkbeck College, and the Institute of Cancer Research, Domainex Ltd. is a Cambridge-based, privately-owned company that provides integrated medicines research services to global pharmaceutical, biotechnology and academic partners. Its services cover a wide span of the drug research value chain, from disease target selection to pre-clinical candidate nomination. Domainex's services include recombinant protein expression and use of its proprietary technology platform, Combinatorial Domain Hunting to identify soluble protein fragments for structural biology and assay development. Hit finding activities encompass assay development and screening utilising its BioassayBuilder, FragmentBuilder and LeadBuilder platforms. The core of the service offering is undertaking multi-parameter medicinal chemistry optimisation of hits and leads with its every compound counts approach, which can save up to 30% on the average industry time from target to candidate.

For more information please visit www.domainex.co.uk